Server: Microsoft-IIS/3.0
Date: Thu, 18 Dec 1997 17:56:45 GMT
Content-Type: text/html
Accept-Ranges: bytes
Last-Modified: Wed, 12 Nov 1997 19:10:06 GMT
Content-Length: 3843

<HTML>
<HEAD>
<META HTTP-EQUIV="Content-Type" CONTENT="text/html; charset=windows-1252">
<META NAME="Generator" CONTENT="Microsoft Word 97">
<TITLE>NTI Press Releases</TITLE>
<META NAME="keywords" CONTENT="biotechnology, rheumatoid arthritis, memantine, neuroprotection, press releases">
<META NAME="description" CONTENT="Recent Press Releases from Neurobiological Technologies, Inc. (NTII)">
<META NAME="Template" CONTENT="C:\Program Files\Microsoft Office\Office\html.dot">
</HEAD>
<BODY LINK="#0000ff" VLINK="#800080" BGCOLOR="#ffffff">

<P ALIGN="CENTER"><IMG SRC="pics/pg6_hdr.gif" WIDTH=459 HEIGHT=49 ALT="Recent Press Releases"><BR>
<A HREF="image.map"><IMG SRC="pics/map.gif" USEMAP="#map" BORDER=0 ISMAP WIDTH=459 HEIGHT=17 ALT=" "></A><map name="map"><area coords="0,0,37,17" href="profile2.htm"><area coords="41,0,82,17" href="pipetxt.htm"><area coords="86,0,134,17" href="fintxt.htm"><area coords="139,0,191,17" href="stock.htm"><area coords="196,0,282,17" href="nrpweb.htm"><area coords="286,0,359,17" href="prespage.htm"><area coords="362,0,410,17" href="glossary.htm"><area coords="413,0,459,17" href="contacts.htm"></map></P>
<add new press release titles after this line>
<P ALIGN="CENTER"><A HREF="enrollment.htm">Neurobiological Technologies, Inc. Completes Enrollment in Phase II Trial for Neuropathic Pain</A></P>
<P ALIGN="CENTER"><A HREF="FQ97.htm">Neurobiological Technologies, Inc. Announces First Quarter Results</A></P>
<P ALIGN="CENTER"><A HREF="ER97.htm">Neurobiological Technologies, Inc. Announces Fiscal Year End Results</A></P>
<P ALIGN="CENTER"><A HREF="pbeii.htm">Neurobiological Technologies, Inc. Starts Phase II Xerecept&trade; Trial; Potential Treatment for Patients with Brain Tumors</A></P>
<P ALIGN="CENTER"><A HREF="evpresign.htm">Neurobiological Technologies, Inc. Executive Vice President Resigns </A></P>
<P ALIGN="CENTER"><A HREF="orphan.htm">Neurobiological Technologies, Inc. Applies for Orphan Drug Status of Xerecept&trade; </A></P>
<P ALIGN="CENTER"><A HREF="tbiind.htm">Neurobiological Technologies, Inc. Files IND for Xerecept&trade; </A></P>
<P ALIGN="CENTER"><A HREF="tbi.html">Neurobiological Technologies, Inc. Xerecept&trade; (CRF) Results Presented At 10th Annual Symposium On Intracranial Pressure</A> </P>
<P ALIGN="CENTER"><A HREF="3q97pr.html">Neurobiological Technologies Reports Third Quarter Results</A></P>
<P ALIGN="CENTER"><A HREF="freiman.html">Neurobiological Technologies, Inc. Elects Veteran Pharmaceutical Executive to Positions of President and CEO</A></P>
<P ALIGN="CENTER"><A HREF="memphii2.html">Neurobiological Technologies, Inc. Starts Phase II Memantine Trial</A></P>
<P ALIGN="CENTER"><A HREF="stock2.html">Neurobiological Technologies, Inc. Announces Resignation of Director and Stock Purchases by Insiders</A></P>
<P ALIGN="CENTER"><A HREF="board2.htm">Paul Freiman and Abraham Sofaer Join Board of Neurobiological Technologies, Inc.</A> </P>
<P ALIGN="CENTER"><A HREF="pr2q.htm">Neurobiological Technologies, Inc. Announces Second Quarter Results</A> </P>
<P ALIGN="CENTER"><A HREF="ra.htm">Neurobiological Technologies, Inc. Announces Results of Rheumatoid Arthritis Trial</A> </P>
<P ALIGN="CENTER"><A HREF="memphii.htm">Neurobiological Technologies, Inc. Starts Phase II Memantine Trial with NIH AIDS Unit</A></P>
<P ALIGN="CENTER"><A HREF="liprsr.htm">NTII Initiates Neuroprotection Research Program with Children's Hospital in Boston</A></P>
<P ALIGN="CENTER">&nbsp;</P>
<P ALIGN="CENTER"><A HREF="profile2.htm">Profile</A> | <A HREF="pipetxt.htm">Pipeline</A> | <A HREF="fintxt.htm">Financial</A> | <A HREF="stock.htm">Stock Info</A> | <A HREF="nrpweb.htm">Neuroprotection</A> | <A HREF="prespage.htm">Press Releases</A> | <A HREF="glossary.htm">Glossary</A> | <A HREF="contacts.htm">Contacts</A> </P></BODY>
</HTML>
